We hypothesized that the systemic effect of CRI involved an in situ vaccine effect, resulting in part from the local administration of RT and i.t. IL-12 acting on the primary tumor, when combined with the systemic srIL-2 and anti-CTLA-4. Here, CTLA4 is linked to neoplasm.